

B/S

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

A. Martin Lerner

Group Art Unit: 1617

Serial No.: 10/060,159

Examiner: Russell Travers

Filed: January 30, 2002

For: METHOD FOR DIAGNOSING AND ALLEVIATING THE SYMPTOMS OF
CHRONIC FATIGUE SYNDROME

Attorney Docket No.: LMA 0113 PUS1

**INFORMATION DISCLOSURE STATEMENT AND
CERTIFICATION UNDER 37 C.F.R. § 1.97(d) AND (e)**

Mail Stop Issue Fee
Commissioner for Patents
U.S. Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and § 1.97-1.98, the references listed and identified on the attached Form PTO/SB08B are being submitted herewith for consideration by the Examiner. This Statement is being filed in accordance with 37 C.F.R. § 1.97(d), i.e., either after the mailing date of a final rejection, or a notice of allowance, but before payment of the issue fee. The undersigned certifies that each item of information contained in this Information Disclosure Statement was not cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge


100.00 0P

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this paper, including all enclosures referred to herein, is being deposited with the United States Postal Service as first-class mail, postage pre-paid, in an envelope addressed to: Mail Stop Issue Fee, Commissioner for Patents, U.S. Patent & Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 on:

April 19, 2004
Date of Deposit

Sangeeta G. Shah
Name of Person Signing


Signature

04/22/2004 WABDEIR1 00000001 10060159

01 FC:1606


of the person signing this statement, was not known to any individual designated in § 1.56 more than three months prior to the filing of this Statement, or was first cited in any communication from a foreign patent office in a counterpart foreign application (copy of communication enclosed) not more than three months prior to the filing of this Statement.

The fee of \$180 pursuant to the provisions of 37 C.F.R. § 1.17(p) is enclosed. Please charge any additional fee or credit any overpayment in connection with this filing to our Deposit Account No. 02-3978. A duplicate of this notice is enclosed for this purpose.

A copy of each reference listed on the attached Form PTO/SB08B is included herewith. Consideration and entry into the record of these references is respectfully requested.

Respectfully submitted,

A. Martin Lerner

By: 

Sangeeta G. Shah

Reg. No. 38,614

Attorney/Agent for Applicant

Date: April 19, 2004

BROOKS KUSHMAN P.C.
1000 Town Center, 22nd Floor
Southfield, MI 48075-1238
Phone: 248-358-4400
Fax: 248-358-3351



Substitute for Form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	LMA 0113 PUS1
-------	---	----	---	------------------------	---------------

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		A. Martin Lerner, Robert G. Deeter, William O'Neill, Howard J. Dworkin, Marcus Zervos, Safedin H. Beqaj, Chung-Ho Chang, and James T. Fitzgerald; HANDBOOK OF CHRONIC FATIGUE SYNDROME, Chapter 15 entitled "Cardiac and Viologic Issues," John Wiley & Sons, Inc., Hoboken, NJ (2003), pp. 304-330.	
		Lerner, A. Martin; Beqaj, Safedin H.; Fitzgerald, James T.; and Deeter, Robert G.; IgM Serum Antibodies to Epstein-Barr Virus are Uniquely Present in a Subset of Patients with the Chronic Fatigue Syndrome, <u>in vivo</u> 18: 101-106 (2004).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.